港股異動 | 昊海生物科技(6826.HK)大漲11% 年度淨利下降 但主營穩步增長
格隆匯3月2日丨昊海生物科技(6826.HK)午盤獲資金炒作明顯,一度放量大漲超12%。現報44.15港元,漲11.07%,暫成交2121.5萬港元,最新總市值78.5億港元。昊海生物科技27日公佈,公司2019年度淨利降10.56%至3.71億元,實現營業總收入16.04億元,同比增長2.94%。報告期內,公司主營業務保持了持續增長的態勢,玻璃酸鈉注射液、外用重組人表皮生長因子和人工晶狀體等主要產品的銷售收入穩步提高。市場人士指出,公司年度淨利降幅在預期之內,值得注意的是,發生的研發費用較同期大幅增加超過20%亦是導致利潤下降的原因。並且公司主營業務穩步增長,未來公司業績增長依舊可期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.